Fully implantable spinal port system for prolonged analgesia in chronic pain syndrome in cancer patients

Abstract

The first experience of the clinic Surgery Naval Military Medical Academy in the treatment of chronic pain in cancer patients with spinal port. In the early days of tumor pain concerned about 50% of patients with advance of – 75% and with terminal cancer and 90%. Oncology patients find the pain as main symptom of the disease. Treatment of chronic pain as the oncological and non-oncological nature is not completely solve the problem. To solve the problem of quality in the management of pain during the remaining life of the patient with cancer stage IV spinal modern port B|«Braun Celsitest 304-20» was used. Camera port is subcutaneously, on the frontaxillary line in the fifth intercostal space projection and was contoured to find it quickly by the patient. Until the end of his life the patient has introduced narcotic analgesic himself. After a short instruction could have done any adult member of the family. The effectiveness of anesthesia was 100% for the rest of his life (in numerological rating scale). Today completely implantable systems of intrathecal drug delivery are good alternative to systematic use of opioids for palliative care format to cancer patients with severe chronic pain syndrome.

Keywords

spinal port, cancer patient, cancer pain, disability, economic damage, spinal port morphine test, malignant tumors, subarachnoid space, Karnofsky scale

References

[1] Клиническая онкология / под ред. Б.Н. Котива, Л.Н. Бисенкова. – СПб.: ВМА, 2008. – 252 с.

[2] Соловьев, И.А. Дифференцированный подход к комбинированному лечению рака прямой кишки: автореф. дис. … д-ра мед. наук / И.А. Соловьев. – СПб.: ВМА, 2010. – 62 с.

[3] Co ff ey, R. J. Mor tal it y as so cia te d wi th imp la nta ti on a nd management of intrathecal opioid drug infusion systems to treat non-cancer pain / R.J. Coffey [et al.] // Anesthesiology. – 2009. – Vol. 111. – P. 881–891.

[4] Cousins, M.J. Intrathecal and epidural administration of opioids / M.J. Cousins, L.E. Mather // Anesthesiology. – 1984. – Vol. 61. – P. 276–310.

[5] Deer, T. Intrathecal drug delivery for treatment of chronic low back pain: report from the National Outcomes Registry for Low Back Pain / T. Deer [et al.] // Pain Med. – 2004. – Vol. 5. – P. 6–13.

[6] Deer, T. Intrathecal therapy for cancer and nonmalignant pain: patient selection and patient management / T. Deer [et al.] // Neuromodulation. – 2002. – Vol. 2. – P. 55–66.

[7] Deer, T.R. A critical time for practice change in the pain treatment continuum: we need to reconsider the role of pumps in the patient care algorithm / Deer T.R. // Pain Med. – 2010. – Vol. 11. – P. 987–990.

[8] Deer, T.R. Consensus guidelines for the selection and implantation of patients with noncancer pain for intrathecal drug delivery / T.R. Deer [et al.] // Pain Physician. – 2010. – Vol. 13. – P. 175–213.

[9] Hassenbusch, S. Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery– report of an expert panel / S. Hassenbusch [et al.] // J. Pain Symptom Manage. – 2004. – Vol. 27. –P. 540–563.

[10] Heart rate variability standarts of measurement, physiological interpretation, and clinical use / Eur. Heart J. – 1996. – Vol. 17. – P. 354–381.

[11] International Association for the Study of Pain. Declaration of Montreal / Accessed Dec. – 2013. – Vol. 9. – P. 31–33.

[12] Joint Commission on Accreditation of Healthcare Organizations. Comprehensive Accreditation Manual for Ambulatory Care. – 1999–2000. – P. 21–29.

[13] Koryachkin, V.A. Epidural and spinal anesthesia: A grant for doctors / V.A. Koryachkin, V.I. Strashnov // [Epidural’naya i spinnomozgovaya anesteziya: Posobie dlya vrachey]. – St. Petersburg: SPb medical publishing house; (in Russian). – 2000. – P. 12–30.

[14] Krames, E. Intrathecal infusional therapies for intractable pain: patient management guidelines / E. Krames // J. Pain. Symptom. Manage. – 1993. – Vol. 8. – P. 451–453.

[15] Krames, E.S. Clinical realities and economic considerations: patient selection in intrathecal therapy / E.S. Krames, K. Olson // J. Pain. Symptom. Manage. – 1997. – Vol. –14. – P. 3–13.

[16] Medtronic 2011 product performance report. Minneapolis, MN: Medtronic Inc. – 2011. – P. 4–10.

[17] Medtronic marketing data. Minneapolis, MN: Medtronic Inc., 2013. – 126 р.

[18] Onofrio, B.M. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin / B.M. Onofrio, T.L. Yaksh, P.G. Arnold // Mayo Clin. Proc. – 1981. – Vol. 56. – P. 516–520.

[19] Prager, J.P. Minimizing the risks of intrathecal therapy / J.P. Prager // Lecture, Scientific Meeting of The North American Neuromodulation Society. – 2009. – P. 9–11.

[20] Rathmell, J.P. Death after initiation of intrathecal drug therapy for chronic pain / J.P. Rathmell, M.J. Miller // Anesthesiology. – 2009. – Vol. 111. – P. 706–708.

RIGHTS & PERMISSIONS

Eco-Vector